lower schreef op 24 november 2016 14:44:
Welke bedrijf zouden ze willen overnemen of dat programma van kopen?
March 16, 2016 – Oss, The Netherlands. ModiQuest Research BV, the Dutch antibody services company, today announced that it will continue its collaboration with Sobi™ aimed at the generation of novel monoclonal antibodies against Sobi target(s). During the new project, ModiQuest will screen their high class in-house phage display libraries, ModiPhageTM. Financials details of the collaboration were not disclosed.
“We are delighted that Sobi has selected ModiQuest Research as antibody generation partner,” said Dr. Jos Raats, Managing Director of ModiQuest Research. “We are very much looking forward to build a long-term partnership with Sobi and to apply our unique antibody technology platform in the field of orphan diseases.”
modiquestresearch.nl/2016/03/modiques...Dat 'monocal antibody' en 'phase display' onderzoek is precies wat Dyax (nu Shire) doet. Daar zit hun 'veelbelovende' DX-2930 (onderzoek SHP643).
To see how antibodies are used, consider the challenge of determining where actin is located in a nerve cell. Actin is a protein that forms part of the cytoskeleton , giving internal structure to the cell much like the human skeleton does. First, purified actin is used to trigger an immune reaction in a
rabbit. The B cells that make the anti-actin antibodies are then isolated
www.biologyreference.com/A-Ar/Antibod...